Evidence map›Paper›PMID 27110267›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2016

Nao-Xue-Shu Oral Liquid Protects and Improves Secondary Brain Insults of Hypertensive Cerebral Hemorrhage.

Hongning Jiang, Ying Qin, Te Liu, Liang Zhang, Mingzhe Wang, Baofeng Qin, Wenfei Jiang, Weilong Liao, Weidong Pan

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Hongning JiangDepartment of Radiology, Shuguang Hospital, Shanghai Traditional Chinese Medicine, Shanghai 201203, China.
Ying QinDepartment of Respiratory Medicine, Pudong Hospital of Traditional Chinese Medicine, Shanghai 201209, China.
Te LiuShanghai Geriatric Institute of Chinese Medicine, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200031, China.
Liang ZhangDepartment of Neurology, Shanghai Seventh Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200137, China.
Mingzhe WangDepartment of Neurology, Shuguang Hospital, Shanghai Traditional Chinese Medicine, Shanghai 201203, China.
Baofeng QinDepartment of Neurology, Shuguang Hospital, Shanghai Traditional Chinese Medicine, Shanghai 201203, China.
Wenfei JiangDepartment of Neurology, Shuguang Hospital, Shanghai Traditional Chinese Medicine, Shanghai 201203, China.
Weilong LiaoDepartment of Neurology, Shuguang Hospital, Shanghai Traditional Chinese Medicine, Shanghai 201203, China.
Weidong PanDepartment of Neurology, Shuguang Hospital, Shanghai Traditional Chinese Medicine, Shanghai 201203, China.
Shanghai University of Traditional Chinese Medicine · CNShuguang Hospital · CNShanghai Traditional Chinese Medicine Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim. To determine one traditional Chinese medicine (TCM) Nao-Xue-Shu oral liquid which protects and improves secondary brain insults (SBI) in hypertensive cerebral hemorrhage (HCH). Methods. 158 patients with HCH were divided into routine clinical medicine plus Nao-Xue-Shu oral liquid (n = 78) as treatment group, and routine clinical medicine (n = 80) only served as the control group. The incidence of SBI and the classification of a favorable prognosis and a bad prognosis using the Glasgow outcome scale (GOS) were assessed to evaluate the clinical effects. The changes of IL-6 and TNF-α levels were determined to study the mechanism of the effects for the TCM. Results. The incidence of SBI at the end of week 2 was 8.97% in the treatment group and 23.75% in the control group, and the difference was significant (P < 0.001). The incidence of a favorable prognosis was 48.72% in the treatment group and 32.72% in the control group, and the difference was significant (P < 0.01) at the end of week 2. These findings indicate clear differences for IL-6 and TNF-α at the end of week 1 and week 2 compared with before treatment for the treatment group and a marked difference at the end of week 2 between the two groups. It also shows a significant difference between the end of week 2 and before treatment for IL-6 and TNF-α for the control group, although the difference was much smaller than the treatment group. Conclusion. Nao-Xue-Shu oral liquid could protect against the occurrence of SBI and improve HCH and SBI patients. It may also decrease the damage and the mass effects of the hematoma by reducing IL-6 and TNF-α to obtain the effects, and thus it is a potentially suitable drug for HCH and SBI.

Identifiers

PMID27110267
PMCPMC4826692
OpenAlexW2305937252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.